Technology selection identified as biggest hurdle in serialization race for compliance
Resourcing the deployment of serialization systems and processes also cited as a significant barrier to compliance with European FMD,
New industry research explores the greatest barriers to serialization success as companies across the pharmaceutical supply chain prepare for new regulations in the US and Europe.
The research, conducted by serialization system provider SEA Vision and life science technology specialist Zenith Technologies, highlights technology selection as the biggest challenge currently faced by the industry, cited by 28% of respondents.
As the industry considers the implications of the European Falsified Medicines Directive (FMD), one quarter of respondents rated understanding global serialization requirements as the biggest challenge they face. Fourteen percent are most concerned by the tight deployment timescales, while 12% believe that resourcing the deployment of serialization systems and processes is the biggest barrier to compliance.
Other cited challenges include establishing lifecycle support for their systems (7%) and selecting an implementation partner (7%).
Commenting on the research, Carlos Machado, serialization director at SEA Vision US, said: “Preparing for serialization is a complex task and it is clear that the challenges that companies must overcome are wide ranging.
“Technology selection and implementation is key to project success, and flexibility and scalability are important factors to consider when selecting a serialization solution that is built for the future. Given the multiple technical and logistical challenges associated with implementing a solution, reputable providers should be able to demonstrate a concrete track record of working across varying global serialization architectures. We expect to see a growing reliance on third party support providers over the coming months as many pharmaceutical manufacturers lack the internal resource and expertise to face the challenge of serialization head on.”
In 2016, SEA Vision and Zenith Technologies formed a global partnership to support pharmaceutical companies with the impending challenge of installing and integrating serialization across drug manufacturing sites.
The collaboration brings together Italian-based SEA Vision’s serialization system along with global Zenith Technologies’ ability to integrate systems and deliver ongoing technical support at a local level.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance